Search

Your search keyword '"Juan Pablo Tartari"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Juan Pablo Tartari" Remove constraint Author: "Juan Pablo Tartari"
44 results on '"Juan Pablo Tartari"'

Search Results

1. Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinicResearch in context

2. Macular vessel density in the superficial plexus is not a proxy of cerebrovascular damage in non-demented individuals: data from the NORFACE cohort

3. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress

4. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline

5. Differences in macular vessel density in the superficial plexus across cognitive impairment: the NORFACE cohort

6. Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer’s disease in individuals with mild cognitive impairment: The NORFACE cohort

7. Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort

8. The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

9. Early detection of amyloid load using 18F-florbetaben PET

10. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative

11. The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment

12. Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

13. Author Correction: Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic

14. Sex, Neuropsychiatric Profiles, and Caregiver Burden in Alzheimer’s Disease Dementia: A Latent Class Analysis

15. Smoking is associated with age at disease onset in Parkinson's disease

16. Combination of white matter hyperintensities and Aβ burden is related to cognitive composites domain scores in subjective cognitive decline: the FACEHBI cohort

17. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline

18. From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery

19. Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia

20. Dementia Care in Times of COVID-19: Experience at Fundació ACE in Barcelona, Spain

21. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative

22. Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort

23. Metabolic syndrome impact on cognitive composites domain scores and on white matter hyperintensities in subjective cognitive decline: The FACEHBI Cohort

24. Comparison of automated CLEIA and manual ELISA immunoassays for CSF AD biomarkers: The Fundació ACE Biomarker Research Program (FACEBREP)

25. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type

26. The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

27. Early detection of amyloid load using 18F-florbetaben PET

28. Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis

29. Author Correction: Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic

30. Early detection of amyloid load using

31. How gender and sex influence clinical trial recruitment in Alzheimer's disease: Findings from Fundació ACE Barcelona Alzheimer Treatment and Research Center

32. Interaction of neuropsychiatric symptoms with APOE e4 and conversion to dementia in MCI patients in a memory clinic

33. The Aβ42/Aβ40 ratio in plasma is associated with amyloid‐PET status and rate of progression in individuals with subjective cognitive decline: The Fundació ACE Healthy Brain Initiative

34. Quantitative thresholds for 18 F‐florbetaben PET for the detection of low amyloid load

35. Gender and sex bias in clinical trial recruitment in Alzheimer's disease: Findings from Fundació ACE

36. Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic

37. Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort

38. Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study

39. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort

40. Cognitive decline in Huntington's disease expansion gene carriers

41. LRP10 in α-synucleinopathies

42. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia

43. Clinical manifestations of intermediate allele carriers in Huntington disease

44. Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic.

Catalog

Books, media, physical & digital resources